Pharmaceutical Research

, Volume 28, Issue 7, pp 1696–1706 | Cite as

Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species

  • Yulia Vugmeyster
  • Pam Szklut
  • David Wensel
  • John Ross
  • Xin Xu
  • Michel Awwad
  • Davinder Gill
  • Lioudmila Tchistiakov
  • Garvin Warner
Research Paper



Anti-Aβ Ab2 (Ab2) is a humanized monoclonal antibody against amino acids 3–6 of primate (but not rodent) amyloid β (Aβ) and is being evaluated for the treatment of Alzheimer’s disease (AD). This study was conducted to predict the human pharmacokinetics of Ab2.


In vivo PK profile of Ab2 in preclinical species and in vitro mechanistic studies in preclinical and human systems were used for pharmacokinetic predictions.


In Tg2576 and PSAPP mice that have ~100-fold higher circulating levels of human Aβ compared to humans, elimination of Ab2 was target-mediated, such that exposure was 5–10 fold lower compared to wild-type rodents or to PDAPP mice that have human Aβ concentrations in plasma similar to humans. In cynomolgus monkeys, the t1/2 of Ab2 was faster (<2.5 days) compared to that of the control antibody (~13 days). The fast elimination of Ab2 in cynomolgus monkeys was linked to off-target binding to cynomolgus monkey fibrinogen that was also causing incomplete recovery of Ab2 in cynomolgus monkey serum in blood partitioning experiments. Ab2 had significantly weaker to undetectable binding to human (and mouse) fibrinogen and had good recovery in human serum in blood partitioning experiments.


These data predict that elimination of Ab2 in healthy or AD humans is expected to be slow, with t1/2 similar to that observed for other humanized antibodies.


Alzheimer’s disease anti-Abeta antibody fibrinogen human PK prediction pharmacokinetics 



All authors are current or former employees of Pfizer, Inc. We thank JANSSEN Alzheimer Immunotherapy (South San Francisco, CA) for their contribution to this study. We also thank Mike Agostino and Michelle Mader for help with sequence alignment, Chris Shea and Nicole Duriga for help with bionalytical assays, and Andrew Hill and Ioannis Moutsatsos for help with protein bioinformatics.


  1. 1.
    Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Games D, Bard F, Grajeda H, Guido T, Khan K, Soriano F, et al. Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1–42. Ann N Y Acad Sci. 2000;920:274–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Lemere CA, Maier M, Jiang L, Peng Y, Seabrook TJ. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. Rejuvenation Res. 2006;9:77–84.PubMedCrossRefGoogle Scholar
  4. 4.
    Jicha GA. Is passive immunization for Alzheimer’s disease ‘alive and well’ or ‘dead and buried’? Expert Opin Biol Ther. 2009;9:481–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Wilcockand DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer’s disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis. 2008;15:555–69.Google Scholar
  6. 6.
    Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med. 1998;4:97–100.PubMedCrossRefGoogle Scholar
  7. 7.
    Irizarry MC, Soriano F, McNamara M, Page KJ, Schenk D, Games D, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci. 1997;17:7053–9.PubMedGoogle Scholar
  8. 8.
    Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer’s disease. J Neurosci. 2001;21:372–81.PubMedGoogle Scholar
  9. 9.
    Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M, et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2006;103:5161–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Golde TE, Das P, Levites Y. Quantitative and mechanistic studies of abeta immunotherapy. CNS Neurol Disord Drug Targets. 2009;8:31–49.PubMedCrossRefGoogle Scholar
  11. 11.
    Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer’s disease mouse models. Faseb J. 2006;20:2576–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Dodel RC, Hampel H, Du Y. Immunotherapy for Alzheimer’s disease. Lancet Neurol. 2003;2:215–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008;31:175–93.PubMedCrossRefGoogle Scholar
  14. 14.
    Gaugler MN, Tracy J, Kuhnle K, Crameri A, Nitsch RM, Mohajeri MH. Modulation of Alzheimer’s pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo. FEBS Lett. 2005;579:753–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Karlnoski RA, Rosenthal A, Alamed J, Ronan V, Gordon MN, Gottschall PE, et al. Deglycosylated anti-Abeta antibody dose-response effects on pathology and memory in APP transgenic mice. J Neuroimmune Pharmacol. 2008;3:187–97.PubMedCrossRefGoogle Scholar
  16. 16.
    Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X. Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology. J Pharm Sci. 99:1028–45.Google Scholar
  17. 17.
    Janus C, Westaway D. Transgenic mouse models of Alzheimer’s disease. Physiol Behav. 2001;73:873–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Lichtlen P, Mohajeri MH. Antibody-based approaches in Alzheimer’s research: safety, pharmacokinetics, metabolism, and analytical tools. J Neurochem. 2008;104:859–74.PubMedCrossRefGoogle Scholar
  19. 19.
    Yu P, Oberto G. Alzheimer’s disease: transgenic mouse models and drug assessment. Pharmacol Res. 2000;42:107–14.PubMedCrossRefGoogle Scholar
  20. 20.
    Davis CB, Garver EM, Kwok DC, Urbanski JJ. Disposition of metabolically radiolabeled CE9.1–a macaque-human chimeric anti-human CD4 monoclonal antibody–in transgenic mice bearing human CD4. Drug metabolism and disposition: the biological fate of chemicals. 1996;24:1032–7.Google Scholar
  21. 21.
    Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. The AAPS Journal. 2008;10:425–30.PubMedCrossRefGoogle Scholar
  22. 22.
    Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, et al. Systemic catabolism of Alzheimer’s Abeta40 and Abeta42. J Biol Chem. 2004;279:45897–908.PubMedCrossRefGoogle Scholar
  23. 23.
    Amris A, Amris CJ. Turnover and distribution of 131-iodine-labelled human fibrinogen. Thromb Diath Haemorrh. 1964;11:404–22.PubMedGoogle Scholar
  24. 24.
    Areekul S, Devakul K, Chongsuphajaisiddhi T, Vivatanasesth P, Kanakakorn K, Kasemsuth R. Metabolism of 131 I-labelled fibrinogen in monkeys infected with Plasmodium coatneyi. Southeast Asian J Trop Med Public Health. 1971;2:455–61.PubMedGoogle Scholar
  25. 25.
    Moza AK, Sapru RP. Turnover of radio-iodinated and biosynthetically labelled fibrinogen in rhesus monkeys. Indian J Med Res. 1982;76:609–17.PubMedGoogle Scholar
  26. 26.
    Negrier C, Rothschild C, Goudemand J, Borg JY, Claeyssens S, Alessi MC, et al. Pharmacokinetics and pharmacodynamics of a new highly secured fibrinogen concentrate. J Thromb Haemost. 2008;6:1494–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Tytgat GN, Collen D, Verstraete M. Metabolism of fibrinogen in cirrhosis of the liver. J Clin Invest. 1971;50:1690–701.PubMedCrossRefGoogle Scholar
  28. 28.
    Bonfanti U, Lamparelli D, Colombo P, Bernardi C. Hematology and serum chemistry parameters in juvenile cynomolgus monkeys (Macaca fascicularis) of Mauritius origin: comparison between purpose-bred and captured animals. J Med Primatol. 2009.Google Scholar
  29. 29.
    Stern RA, Trojanowski JQ, Lee VM. Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood. FEBS Lett. 1990;264:43–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Merkle DL, Cheng CH, Castellino FJ, Chibber BA. Modulation of fibrin assembly and polymerization by the beta-amyloid of Alzheimer’s disease. Blood Coagul Fibrinolysis. 1996;7:650–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D et al. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer’s disease. Neuron. 66:695–709.Google Scholar
  32. 32.
    Ghiso J, Rostagno A, Gardella JE, Liem L, Gorevic PD, Frangione B. A 109-amino-acid C-terminal fragment of Alzheimer’s-disease amyloid precursor protein contains a sequence, -RHDS-, that promotes cell adhesion. Biochem J. 1992;288(Pt 3):1053–9.PubMedGoogle Scholar
  33. 33.
    Springer TA, Zhu J, Xiao T. Structural basis for distinctive recognition of fibrinogen gamma C peptide by the platelet integrin alphaIIbbeta3. J Cell Biol. 2008;182:791–800.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Yulia Vugmeyster
    • 1
  • Pam Szklut
    • 1
  • David Wensel
    • 1
  • John Ross
    • 2
  • Xin Xu
    • 1
  • Michel Awwad
    • 1
  • Davinder Gill
    • 2
  • Lioudmila Tchistiakov
    • 2
  • Garvin Warner
    • 3
  1. 1.Department of Pharmacokinetics, Dynamics, and MetabolismPfizer Inc.AndoverUSA
  2. 2.Department of Global Biotherapeutics TechnologiesPfizer Inc.CambridgeUSA
  3. 3.Department of Drug Safety Research and DevelopmentPfizer Inc.AndoverUSA

Personalised recommendations